170 related articles for article (PubMed ID: 33009434)
1. Serial changes in the aqueous IL-10 level after intravitreal methotrexate injection as an indicator of primary vitreoretinal lymphoma recurrence.
Park YG; Park WK; Kim RY; Kim M; Park YH
Sci Rep; 2020 Oct; 10(1):15992. PubMed ID: 33009434
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of intravitreal methotrexate for vitreo-retinal lymphoma - 20 years of experience.
Habot-Wilner Z; Frenkel S; Pe'er J
Br J Haematol; 2021 Jul; 194(1):92-100. PubMed ID: 33900619
[TBL] [Abstract][Full Text] [Related]
3. Changes in choroidal vascular structure from vitreoretinal lymphoma and the intraocular cytokine level associated with clinical resolution after intravitreal methotrexate treatment.
Kim RY; Park JH; Kim M; Park YG; Cho SG; Park YH
PLoS One; 2021; 16(11):e0260469. PubMed ID: 34813633
[TBL] [Abstract][Full Text] [Related]
4. Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study.
Lam M; Touitou V; Choquet S; Cassoux N; Ghesquières H; Kodjikian L; Schmitt A; Gattoussi S; Tabouret É; Sampo M; Blonski M; Angioi-Duprez K; Houot R; Mouriaux F; Gyan E; Le Lez ML; Moles MP; Croisé F; Chauchet A; Schwartz C; Ahle G; Meyer L; Gressin R; Chiquet C; Oberic L; Ollé P; Marolleau JP; Jany B; Tempescul A; Cochener B; Damaj G; Quintyn JC; Moluçon-Chabrot C; Rousseau E; Franciane P; Schneider C; Massé H; Tamburini-Bonnefoy J; Brézin A; Fornecker LM; Ballonzoli L; Le Garff-Tavernier M; Hoang-Xuan K; Bodaghi B; Soussain C; Houillier C
Am J Hematol; 2021 Jul; 96(7):823-833. PubMed ID: 33864703
[TBL] [Abstract][Full Text] [Related]
5. A proposed protocol of intravitreal injection of methotrexate for treatment of primary vitreoretinal lymphoma.
Zhou N; Xu X; Liu Y; Wang Y; Wei W
Eye (Lond); 2022 Jul; 36(7):1448-1455. PubMed ID: 34211136
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal observation of OCT imaging is a valuable tool to monitor primary vitreoretinal lymphoma treated with intravitreal injections of methotrexate.
Zhao H; Wang X; Mao Y; Peng X
BMC Ophthalmol; 2020 Jan; 20(1):10. PubMed ID: 31906917
[TBL] [Abstract][Full Text] [Related]
7. Intraocular chemotherapy for vitreoretinal lymphoma: A review.
Kvopka M; Lake SR; Smith JR
Clin Exp Ophthalmol; 2020 Mar; 48(2):240-248. PubMed ID: 31680408
[TBL] [Abstract][Full Text] [Related]
8. Logistic Regression Classification of Primary Vitreoretinal Lymphoma versus Uveitis by Interleukin 6 and Interleukin 10 Levels.
Kuo DE; Wei MM; Knickelbein JE; Armbrust KR; Yeung IYL; Lee AY; Chan CC; Sen HN
Ophthalmology; 2020 Jul; 127(7):956-962. PubMed ID: 32197914
[TBL] [Abstract][Full Text] [Related]
9. Prognosis, Risk Factors, and Clinical Features of Intraocular Recurrence in Primary Vitreoretinal Lymphoma.
Liu S; Jiang T; Gu J; Zhou X; Chen W; Ping B; Zhou Y; Zhang T; Huang X; Xu G; Chang Q
Ophthalmol Retina; 2024 Apr; 8(4):317-324. PubMed ID: 37918656
[TBL] [Abstract][Full Text] [Related]
10. High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma.
Akiyama H; Takase H; Kubo F; Miki T; Yamamoto M; Tomita M; Mochizuki M; Miura O; Arai A
Cancer Sci; 2016 Oct; 107(10):1458-1464. PubMed ID: 27412324
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse.
Klimova A; Heissigerova J; Rihova E; Brichova M; Pytlik R; Spicka I; Mrazova K; Karolova J; Svozilkova P
Br J Ophthalmol; 2018 Nov; 102(11):1579-1585. PubMed ID: 29378728
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics of Primary Vitreoretinal Lymphoma in an Indian Population.
Mahajan S; Nijhawan R; Rajwanshi A; Karkhur S; Mulkutar S; Dogra M; Lal V; Gupta V; Gupta A
Ocul Immunol Inflamm; 2017 Oct; 25(5):633-638. PubMed ID: 27003620
[TBL] [Abstract][Full Text] [Related]
13. Primary Vitreoretinal Lymphoma in HIV Infection.
Steffen J; Coupland SE; Smith JR
Ocul Immunol Inflamm; 2021 Apr; 29(3):621-627. PubMed ID: 32453669
[No Abstract] [Full Text] [Related]
14. Serial Detection of
Choi S; Shin S; Lee ST; Lee J; Lee JS; Kim B; Lee CS
Ocul Immunol Inflamm; 2021 Apr; 29(3):485-489. PubMed ID: 32965155
[TBL] [Abstract][Full Text] [Related]
15. Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma.
Hashida N; Nakai K; Saitoh N; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2014 Apr; 252(4):687-93. PubMed ID: 24549401
[TBL] [Abstract][Full Text] [Related]
16. Primary Vitreoretinal Lymphoma Therapy Monitoring: Significant Vitreous Haze Reduction After Intravitreal Rituximab.
Kakkassery V; Heindl LM; Rokohl AC; Chronopoulos A; Schutz JS; Ranjbar M; Schargus M; Böker A; Winterhalter S; Stübiger N
Neurosignals; 2021 May; 29(S1):1-7. PubMed ID: 33945240
[TBL] [Abstract][Full Text] [Related]
17. Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018.
Castellino A; Pulido JS; Johnston PB; Ristow KM; Nora Bennani N; Inwards DJ; Macon WR; Micallef INM; King RL; Salomao DR; Witzig TE; Habermann TM; Nowakowski GS
Am J Hematol; 2019 Mar; 94(3):291-298. PubMed ID: 30516868
[TBL] [Abstract][Full Text] [Related]
18. Treatment of primary intraocular lymphoma with intravitreal methotrexate.
Sou R; Ohguro N; Maeda T; Saishin Y; Tano Y
Jpn J Ophthalmol; 2008; 52(3):167-174. PubMed ID: 18661266
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Analysis of Ocular Manifestation and Interleukin During Intravitreal Treatment of Vitreoretinal Lymphoma With Methotrexate.
Gu J; Jiang T; Liu S; Chen X; Wang Z; Zhang P; Wang L; Jiang R; Huang X; Xu G; Chang Q
Am J Ophthalmol; 2023 Jul; 251():189-196. PubMed ID: 36963600
[TBL] [Abstract][Full Text] [Related]
20. Clinical Experience in a Large Cohort of Patients with Vitreoretinal Lymphoma in a Single Center.
Giuffrè C; Cicinelli MV; Marchese A; Modorati GM; Brambati M; Ferreri AJM; Calimeri T; Ponzoni M; Bandello F; Miserocchi E
Ocul Immunol Inflamm; 2021 Apr; 29(3):472-478. PubMed ID: 32845738
[No Abstract] [Full Text] [Related]
[Next] [New Search]
